# LDHB Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The LDHB gene encodes the B subunit of lactate dehydrogenase (LDH), a critical enzyme catalyzing the reversible conversion of lactate to pyruvate, thereby regulating cellular redox homeostasis and mitochondrial fuel selection. - LDHB's kinetic properties favor lactate oxidation, and its expression is dynamically regulated by factors including exercise, hormonal cues, and epigenetic silencing, with its locus on chromosome 12p12.1 frequently altered in cancers. - Beyond its metabolic role, LDHB is a key mediator of histone lactylation, an epigenetic modification influencing gene expression in pathways critical for tumor progression, immune evasion (e.g., PD-L1 upregulation), and therapy resistance. - Pathogenic alterations in LDHB include rare germline mutations causing exertional myoglobinuria and somatic mutations or epigenetic silencing (promoter hypermethylation) in various cancers, leading to altered metabolic phenotypes and clinical outcomes. - LDHB is a significant biomarker in testicular germ cell tumors (serum LDH) and a target for therapeutic intervention in specific cancers like triple-negative breast cancer and ovarian cancer, where its inhibition can impair tumor growth or enhance immune responses. - Dysregulation of LDHB is implicated in neurodegenerative disorders, sepsis, alcoholic liver disease, and osteoarthritis, highlighting its broad clinical significance beyond oncology and its role in fundamental cellular processes. --- ## Executive Summary & Key Metadata The **LDHB** gene encodes the B (heart, H) subunit of lactate dehydrogenase (LDH; EC 1.1.1.27), a tetrameric oxidoreductase that catalyzes the reversible interconversion of pyruvate and lactate with the concomitant redox exchange of NADH/NAD⁺. While the A subunit (LDHA) preferentially reduces pyruvate to lactate under anaerobic conditions, the B subunit (LDHB) exhibits a higher affinity for lactate and NAD⁺, favoring the oxidative conversion of lactate to pyruvate. This kinetic asymmetry positions LDHB as a central node in cellular redox homeostasis, mitochondrial fuel selection, and epigenetic regulation via lactylation. LDHB is not merely a housekeeping metabolic enzyme; its expression is dynamically regulated by exercise, hormonal cues, oncogenic signaling, and epigenetic silencing in multiple malignancies. The gene is located on chromosome 12p12.1, a region frequently deleted or subject to loss of heterozygosity in cancers. LDHB has emerged as a critical determinant of tumor progression, immune evasion, and therapy resistance, as well as a biomarker for testicular germ cell tumors, breast cancer, and hepatocellular carcinoma. This reference manual provides an exhaustive, biophysically detailed analysis of the LDHB gene, from its genomic architecture and 3D protein structure to its roles in signaling networks, pathogenic mutations, and pharmacogenomic targeting. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | LDHB | | **UniProt Accession** | P07195 | | **Representative PDB ID** | 1I10 (human LDHB tetramer) | | **Chromosomal Locus** | 12p12.1 (GRCh38: chr12:21,635,957–21,657,562) | | **Primary Molecular Function** | L-lactate:NAD⁺ oxidoreductase; catalyzes lactate → pyruvate oxidation; histone lactylation modulator | | **Disease & Pathology Associations** | Testicular germ cell tumors, triple-negative breast cancer, hepatocellular carcinoma, ovarian cancer immune escape, neurodegenerative disorders, sepsis, alcoholic liver disease, osteoarthritis | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Synteny The human LDHB gene maps to the short arm of chromosome 12 at band p12.1. Early somatic cell hybridization studies established the regional assignment of LDHB to chromosome 12, along with TPI1, GAPDH, SHMT, and PEPB. Subsequent high-resolution mapping refined the locus to 12p12.1, a region spanning approximately 21.6 kb of genomic DNA on the plus strand (GRCh38: chr12:21,635,957–21,657,562). The gene is oriented telomere-to-centromere, with neighboring genes including **TPI1** (triosephosphate isomerase 1) and **GAPDH** (glyceraldehyde-3-phosphate dehydrogenase), forming a conserved glycolytic gene cluster. This syntenic arrangement is evolutionarily ancient; comparative mapping in sheep, cattle, rabbits, and foxes has demonstrated conserved linkage groups involving LDHB, TPI, PEPB, and GAPD. In sheep, LDHB is syntenic with PEPB and TPI, and further analysis revealed synteny between COL2A1 and the LDHB-PEPB-TPI-GAPD-LALBA-IGF1 group. In rabbits, LDHB-TPI forms a syntenic group distinct from LDHA-ACP2. This conserved clustering suggests shared regulatory elements or a common evolutionary origin for these metabolically related genes. ### 1.2 Gene Structure and Promoter Architecture The LDHB gene comprises **7 exons and 6 introns**, spanning approximately 21.6 kb. The transcript (NM_002300.9) is 1,614 nucleotides in length, with a 5' untranslated region (UTR) of ~100 nucleotides, a coding sequence (CDS) of 999 nucleotides encoding a 334-amino acid protein, and a 3' UTR of ~515 nucleotides. The promoter region lacks a canonical TATA box but contains multiple GC-rich elements, including Sp1 binding sites, consistent with its widespread, housekeeping-like expression. However, LDHB expression is far from constitutive; it is subject to tissue-specific and condition-dependent regulation. **Key promoter and enhancer elements:** - **Sp1/GC-boxes**: Located within −200 to −50 bp relative to the transcription start site (TSS), these elements are essential for basal transcription. - **PPARβ/δ response elements (PPREs)**: The nuclear receptor PPARβ/δ, in cooperation with AMPK and MEF2, directly activates LDHB transcription in skeletal muscle. This regulatory axis is critical for exercise-induced LDHB upregulation. - **PGC-1α coactivation**: PGC-1α (PPARGC1A) coactivates PPARβ/δ at the LDHB promoter, linking mitochondrial biogenesis to lactate oxidation. - **STAT1 binding sites**: In prostate cancer, FGF signaling suppresses LDHB via STAT1-dependent transcriptional repression. STAT1 binds to the LDHB promoter and recruits co-repressors, reducing transcription. - **Hypoxia response elements (HREs)**: Although LDHB is generally considered hypoxia-repressed (in contrast to LDHA, which is HIF-1α-induced), the promoter contains putative HREs that may mediate context-dependent regulation. In alcoholic liver disease, LDHB is identified as a hypoxia- and lactylation-related gene. - **CpG islands**: A large CpG island spans the promoter and first exon. Hypermethylation of this island leads to epigenetic silencing of LDHB in multiple cancers, including hepatocellular carcinoma, breast cancer, and colon adenocarcinoma. ### 1.3 Alternative Splicing and Isoforms The primary LDHB transcript undergoes alternative splicing, generating multiple mRNA isoforms. The canonical isoform (ENST00000229270.9) encodes the full-length 334-amino acid protein. A second isoform, lacking exon 6, produces a truncated protein with a disrupted catalytic domain; this isoform is expressed at low levels in testis and may function as a dominant-negative regulator. Additionally, the 3' UTR of LDHB contains multiple microRNA (miRNA) binding sites, including those for **miR-375**, **miR-4677-3p**, and **miR-30 family members**. These miRNAs regulate LDHB expression post-transcriptionally, often in a tissue-specific manner. For instance, miR-375 directly targets the LDHB 3' UTR in maxillary sinus squamous cell carcinoma, reducing LDHB protein levels and altering glycolytic flux. In breast cancer, miR-4677-3p downregulates LDHB, contributing to paclitaxel resistance. ### 1.4 Allelic Variation and Expression Quantitative Trait Loci (eQTLs) LDHB exhibits allele-specific expression (ASE) in certain tissues. In Nelore cattle, LDHB shows ASE in the liver of animals at the extremes of feed efficiency, suggesting cis-regulatory variants that modulate transcription. In yaks, the LDHB gene is polymorphic, with multiple alleles encoding electrophoretically distinct H subunits; heterozygous individuals display multiple LDH1 (H₄) isoenzyme bands on native polyacrylamide gels. These polymorphisms are associated with differential catalytic activity and may influence metabolic adaptation to high-altitude hypoxia. In humans, GTEx data reveal significant eQTLs in the LDHB locus, particularly in skeletal muscle, heart, and liver, where common SNPs (e.g., rs11045709) are associated with LDHB expression levels. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Organization The LDHB protein (UniProt P07195) is a 334-amino acid polypeptide with a molecular weight of approximately 36.6 kDa. The protein folds into two distinct domains: 1. **NAD⁺-binding domain (Rossmann fold)**: Residues **1–140** (N-terminus). This domain adopts a classic dinucleotide-binding fold consisting of a six-stranded parallel β-sheet flanked by α-helices. The conserved glycine-rich motif **GxGxxG** (residues 27–32: GATGIG) forms the phosphate-binding loop (P-loop) that interacts with the pyrophosphate moiety of NAD⁺. The adenine ring of NAD⁺ is accommodated in a hydrophobic pocket formed by residues Val-30, Ile-53, and Val-138. 2. **Catalytic/substrate-binding domain**: Residues **141–334** (C-terminus). This domain contains the active site cleft, which binds the pyruvate/lactate substrate. Key catalytic residues include: - **Arg-106**: Stabilizes the carboxylate group of pyruvate/lactate. - **His-193**: Acts as the proton donor/acceptor in the hydride transfer mechanism. - **Asp-168**: Positions His-193 via a hydrogen bond network. - **Arg-169**: Coordinates the substrate and stabilizes the transition state. The active site is located at the interface between the two domains, with a conformational change (domain closure) occurring upon substrate binding. The tetramerization interface is formed primarily by residues in the C-terminal domain, particularly the αF-helix (residues 250–270) and the βG-βH loop (residues 280–300). ### 2.2 Quaternary Structure and Isoenzyme Assembly Functional LDH is a **tetramer** of approximately 140 kDa. The B subunit (H) can homotetramerize to form **LDH-1 (H₄)** or co-assemble with the A subunit (M) to form heterotetramers: **LDH-2 (H₃M₁)**, **LDH-3 (H₂M₂)**, and **LDH-4 (H₁M₃)**. The A subunit (LDHA, UniProt P00338) shares ~75% sequence identity with LDHB but differs in substrate affinity and allosteric regulation. The H₄ homotetramer is strongly inhibited by high pyruvate concentrations (substrate inhibition), whereas the M₄ homotetramer is not. This kinetic difference is physiologically significant: H₄ is abundant in aerobic tissues (heart, brain, kidney), where it favors lactate oxidation, while M₄ predominates in anaerobic tissues (skeletal muscle, liver), where it favors pyruvate reduction. The crystal structure of human LDHB (PDB: 1I10) reveals a tetramer with 222-point group symmetry. Each subunit contributes to two distinct dimer interfaces: the "P-axis" interface (involving the N-terminal arm and helix α2) and the "Q-axis" interface (involving the C-terminal domain). The active sites are arranged such that the tetramer has four independent catalytic clefts, each accessible from the solvent. ### 2.3 Post-Translational Modifications LDHB is subject to several post-translational modifications that modulate its activity, stability, and subcellular localization: - **Acetylation**: Acetylation at Lys-5 and Lys-318 has been detected by mass spectrometry. Acetylation at Lys-318, located near the C-terminus, reduces catalytic activity by disrupting the tetramerization interface. - **Phosphorylation**: LDHB is phosphorylated at Ser-161 by AMPK under conditions of energy stress. This phosphorylation increases LDHB activity, promoting lactate oxidation and mitochondrial respiration. - **Lactylation**: LDHB itself can be lactylated at Lys residues (e.g., Lys-114), a modification that may affect its enzymatic activity and protein-protein interactions. This is part of a broader regulatory loop where LDHB-generated lactate serves as the substrate for histone lactylation. - **Oxidation**: Cys-164 is susceptible to oxidative modification (S-nitrosylation, S-glutathionylation) under conditions of oxidative stress, leading to enzyme inactivation. This is particularly relevant in neurodegeneration, where LDHB deficiency exacerbates mitochondrial oxidative stress. ### 2.4 Interactive 3D Visualizer For an interactive exploration of the LDHB protein structure, including domain architecture, active site residues, and tetramer assembly, use the following tool: [Interactive 3D Protein Visualizer: Load LDHB (PDB: 1I10)](/tools/protein-structure-viewer?source=alphafold&accession=P07195) This visualizer allows users to: - Rotate and zoom the LDHB tetramer. - Highlight the NAD⁺-binding domain (residues 1–140) and catalytic domain (residues 141–334). - Display the active site residues (Arg-106, His-193, Asp-168, Arg-169). - Superimpose the LDHB structure with LDHA to compare active site geometries. - Visualize known pathogenic mutations (e.g., Arg-106Cys, His-193Tyr) in the context of the 3D structure. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Core Enzymatic Function and Metabolic Flux LDHB catalyzes the final step of glycolysis in reverse: the oxidation of L-lactate to pyruvate, with the reduction of NAD⁺ to NADH. The equilibrium constant of this reaction strongly favors lactate formation (Keq ≈ 3.6 × 10⁴ M⁻¹ at pH 7.0), but the H₄ isoenzyme has a ~10-fold lower Km for lactate (5–10 mM) compared to the M₄ isoenzyme (20–30 mM), allowing H₄ to operate in the oxidative direction under physiological lactate concentrations. This reaction is central to the **lactate shuttle** concept, where lactate produced in glycolytic cells (e.g., fast-twitch muscle, tumor cells) is exported and taken up by oxidative cells (e.g., heart, slow-twitch muscle, neurons) for use as a respiratory fuel. In skeletal muscle, LDHB expression is induced by exercise. Six weeks of specific low-intensity training in high-level rowers significantly increased LDHB gene expression, correlating with improved aerobic capacity parameters. Mechanistically, exercise activates the PPARβ/δ-AMPK-MEF2 axis, which directly upregulates LDHB transcription. The exercise-induced increase in LDHB enhances the capacity of muscle to oxidize lactate, thereby improving mitochondrial function and fatigue resistance. ### 3.2 LDHB in Mitochondrial Function and Oxidative Phosphorylation Beyond its cytosolic role, LDHB is localized to the mitochondrial intermembrane space and matrix, where it participates in the **intracellular lactate shuttle**. Mitochondrial LDHB converts lactate to pyruvate, which then enters the TCA cycle via pyruvate dehydrogenase (PDH). This pathway is particularly important in neurons, where lactate derived from astrocytes is a major energy substrate. LDHB deficiency in the adult mouse brain leads to mitochondrial dysfunction, increased oxidative stress, and neurodegeneration. Specifically, LDHB knockout mice exhibit: - Reduced mitochondrial complex I and IV activities. - Increased reactive oxygen species (ROS) production. - Impaired ATP synthesis. - Activation of the NLRP3 inflammasome and neuroinflammatory responses. These findings establish LDHB as a critical neuroprotective enzyme, linking glycolytic metabolism to mitochondrial health. ### 3.3 LDHB and Histone Lactylation: An Epigenetic Regulatory Axis A paradigm-shifting discovery is the role of LDHB in **histone lactylation** (Kla), a novel epigenetic modification. Lactate, produced by LDHA or taken up from the microenvironment, is converted to lactyl-CoA, which serves as the donor for lysine lactylation of histones. LDHB, by controlling the intracellular lactate/pyruvate ratio, directly modulates the availability of lactate for this modification. In ovarian cancer, LDHB mediates histone lactylation to activate PD-L1 expression, promoting immune escape. Mechanistically, LDHB-generated lactate enhances H3K18la at the PD-L1 promoter, increasing PD-L1 transcription and suppressing T-cell activity. Silencing LDHB reduces H3K18la, downregulates PD-L1, and restores T-cell-mediated cytotoxicity. Similarly, in acetaminophen-induced liver injury, PGC-1α loss promotes mitochondrial protein lactylation via the LDHB-lactate axis. LDHB is upregulated in response to APAP-induced stress, leading to increased lactate production and mitochondrial protein lactylation, which exacerbates mitochondrial dysfunction and hepatocyte death. In non-small cell lung cancer (NSCLC), histone lactylation driven by LDHB upregulates YTHDF2, an m6A reader, which in turn promotes glycolysis and stemness by recognizing m6A-modified SFRP2 mRNA. This establishes a positive feedback loop: LDHB → histone lactylation → YTHDF2 → glycolysis → lactate → further lactylation. In osteoarthritis, LDHB-mediated histone lactylation regulates chondrocyte ferroptosis. LDHB knockdown reduces H3K18la levels, leading to altered expression of ferroptosis-related genes (e.g., GPX4, ACSL4) and increased chondrocyte death, contributing to cartilage degeneration. In hepatocellular carcinoma, histone lactylation driven by LDHB upregulates USP34, a deubiquitinase that promotes cisplatin resistance. This highlights the clinical relevance of the LDHB-lactylation axis in chemoresistance. ### 3.4 LDHB in the FGF/STAT1 Signaling Pathway In prostate cancer, the fibroblast growth factor (FGF) pathway regulates glycolysis by reciprocally modulating LDHA and LDHB expression. FGF1, which is upregulated during prostate cancer progression, activates STAT1, which in turn: - **Activates LDHA transcription** (via STAT1 binding to the LDHA promoter). - **Suppresses LDHB transcription** (via STAT1 binding to the LDHB promoter and recruiting co-repressors). This shift from LDHB to LDHA expression promotes aerobic glycolysis (the Warburg effect), increasing lactate production and tumor growth. The FGF-STAT1-LDHB axis represents a potential therapeutic target; inhibiting STAT1 or FGF signaling could restore LDHB expression and reverse the glycolytic phenotype. ### 3.5 LDHB in mTOR Signaling and Tumorigenesis LDHB is critical for hyperactive mTOR-mediated tumorigenesis. In cells with constitutive mTOR activation (e.g., due to TSC1/2 loss), LDHB expression is upregulated, and this upregulation is required for the transformed phenotype. Mechanistically, mTORC1 activates HIF-1α, which induces LDHA but represses LDHB; however, in certain contexts, mTORC1 also activates c-Myc, which can upregulate LDHB. The balance between LDHA and LDHB determines the metabolic fate of glucose: high LDHA/LDHB ratio favors glycolysis, while low ratio favors oxidative phosphorylation. LDHB knockdown in mTOR-hyperactive cells reduces lactate oxidation, impairs mitochondrial function, and suppresses tumor growth in xenograft models. ### 3.6 Protein-Protein Interaction Networks LDHB interacts with a diverse set of proteins, as cataloged in BioGRID and STRING databases. Key interactions include: - **LDHA**: Forms heterotetramers (H₃M₁, H₂M₂, H₁M₃), modulating kinetic properties. - **PGC-1α**: Coactivator that regulates LDHB transcription. - **PPARβ/δ**: Nuclear receptor that directly binds the LDHB promoter. - **SLC2A6 (GLUT6)**: Regulates myoblast differentiation by targeting LDHB. SLC2A6 knockdown reduces LDHB expression, impairing myogenic differentiation. - **TXNIP**: A tumor suppressor that regulates glucose metabolism; LDHB is among its downstream targets. - **p53**: Under conditions of DNA damage, p53 represses LDHB expression, shifting metabolism toward glycolysis. - **HSPA1A/HSPB1**: Heat shock proteins co-regulated with LDHB in response to exercise training. ### 3.7 LDHB in Immune Cell Function LDHB expression in tumor cells modulates anti-tumor immunity. In breast cancer, decreased LDHB expression in tumor cells causes NK cell activation and promotes tumor progression. Mechanistically, LDHB-low tumor cells produce more lactate, which acidifies the tumor microenvironment and suppresses NK cell cytotoxicity. Paradoxically, this immune suppression promotes tumor growth, as the reduced NK cell activity allows tumor cells to evade immune surveillance. In ovarian cancer, LDHB promotes immune escape by activating PD-L1 via histone lactylation. In clear cell renal cell carcinoma, LDHA/LDHB expression correlates with tumor-immune infiltration and prognosis. These findings position LDHB as a key regulator of the tumor-immune interface. ### 3.8 LDHB in Circadian Rhythm and Metabolic Regulation LDHB expression exhibits circadian rhythmicity in multiple tissues. In melanoma, circadian rhythm genes, including LDHB, are dysregulated, and LDHB is part of a circadian rhythm-related gene signature for diagnosis and prognosis. The circadian regulation of LDHB may be mediated by CLOCK/BMAL1, which bind E-box elements in the LDHB promoter. Disruption of circadian rhythms alters LDHB expression, contributing to metabolic dysregulation and cancer progression. ### 3.9 Mermaid Diagram: LDHB Signaling and Regulatory Network ```mermaid flowchart TD A["Exercise / PPARβ/δ activation"] -->|"AMPK, MEF2"| B["LDHB transcription ↑"] C["FGF signaling"] -->|"STAT1"| D["LDHB transcription ↓"] E["Hypoxia / HIF-1α"] -->|"miR-375, miR-4677-3p"| F["LDHB mRNA ↓"] G["Epigenetic silencing / CpG methylation"] --> H["LDHB expression ↓"] B --> I["LDHB protein"] D --> I F --> I H --> I I -->|"Lactate → Pyruvate"| J["Mitochondrial respiration"] I -->|"Lactate availability"| K["Histone lactylation"] K -->|"H3K18la"| L["PD-L1 ↑, YTHDF2 ↑, USP34 ↑"] L --> M["Immune escape, Chemoresistance, Glycolysis"] I -->|"NAD+/NADH balance"| N["Redox homeostasis"] I -->|"Mitochondrial function"| O["ATP synthesis, ROS control"] O -->|"Deficiency"| P["Neurodegeneration, Oxidative stress"] I -->|"mTOR signaling"| Q["Tumorigenesis"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations and Inherited Disorders Unlike LDHA, which is associated with a rare glycogen storage disease (Glycogen Storage Disease XI), germline mutations in LDHB are extremely rare and have not been definitively linked to a Mendelian disorder. However, several lines of evidence suggest that LDHB variants may contribute to complex disease susceptibility: - **LDHB deficiency**: Complete LDHB deficiency has been reported in a few individuals, presenting with exertional myoglobinuria and exercise intolerance. These individuals lack the H₄ isoenzyme in erythrocytes and muscle, leading to impaired lactate oxidation and excessive lactate accumulation during exercise. - **Neurodegeneration**: LDHB deficiency in mice causes mitochondrial dysfunction and neurodegeneration. In humans, reduced LDHB expression in the brain is associated with Alzheimer's disease and other neurodegenerative conditions. A genome-wide CRISPR screen identified LDHB as a modulator of amyloid precursor protein (APP) processing, linking LDHB to Alzheimer's disease pathogenesis. - **Suicide attempt severity**: A genetic association study identified LDHB as one of the genes with genetic overlap between suicide attempt severity and major depression. While the functional significance is unclear, this suggests a potential role for LDHB in neuropsychiatric disorders. ### 4.2 Somatic Mutations in Cancer Somatic mutations in LDHB are infrequent but recurrent in certain cancer types. Analysis of TCGA data reveals: - **Missense mutations**: The most common somatic mutations are missense changes, with hotspots at Arg-106, His-193, and Asp-168 (the catalytic residues). These mutations are predicted to be deleterious (CADD scores > 20) and likely reduce or abolish enzymatic activity. - **Arg-106Cys (R106C)**: Disrupts substrate binding; found in ~1% of colorectal cancers. - **His-193Tyr (H193Y)**: Abolishes catalytic activity; found in gastric cancer. - **Asp-168Asn (D168N)**: Disrupts the proton relay network; found in lung adenocarcinoma. - **Frameshift and nonsense mutations**: These are enriched in microsatellite-unstable (MSI) tumors, particularly colorectal and endometrial cancers. The LDHB coding region contains a poly-A tract (nucleotides 100–106) that is prone to frameshift mutations in MSI tumors. - **Copy number alterations**: Hemizygous deletions of the 12p12.1 region, encompassing LDHB, are common in breast cancer, hepatocellular carcinoma, and prostate cancer. These deletions result in reduced LDHB expression, promoting the Warburg effect. ### 4.3 Epigenetic Silencing as a "Functional Mutation" In many cancers, LDHB is silenced not by mutation but by **promoter hypermethylation**. This is particularly well-documented in: - **Hepatocellular carcinoma (HCC)**: LDHB is epigenetically silenced in HCC, and low LDHB expression is associated with poor prognosis. Silencing of LDHB remodels the tumor microenvironment, promoting immune evasion and tumor progression. - **Breast cancer**: LDHB expression is decreased in breast tumors, and this decrease is associated with resistance to neoadjuvant chemotherapy. In triple-negative breast cancer (TNBC), LDHB is an essential gene, and its silencing impairs tumor growth. However, in ER-positive breast cancer, LDHB silencing is associated with tamoxifen resistance. - **Colon adenocarcinoma (COAD)**: Integrative bioinformatics analysis reveals that LDHB is downregulated in COAD, and low LDHB expression correlates with poor survival. - **Glioblastoma (GBM)**: LDHB is part of a glycolysis-related gene signature that predicts prognosis in GBM. ### 4.4 LDHB in Testicular Germ Cell Tumors (TGCT) LDHB has a unique role in testicular germ cell tumors (TGCT). Type 2 TGCTs (seminomas and non-seminomas) have high RNA expression of LDHB, and serum LDH (predominantly LDH-1, the H₄ isoenzyme) is a well-established tumor marker. The high LDHB expression in TGCTs is driven by the transcription factor NANOG, which is essential for pluripotency. LDHB expression correlates with tumor stage and is used clinically to monitor treatment response and detect relapse. Interestingly, the high LDHB expression in TGCTs contrasts with the low expression in most other solid tumors, suggesting a context-dependent role for LDHB in tumor biology. ### 4.5 LDHB in Renal Cell Carcinoma (RCC) In clear cell renal cell carcinoma (ccRCC), LDHA and LDHB have distinct prognostic and immunological roles. High LDHA expression is associated with poor prognosis, while high LDHB expression is associated with better prognosis. LDHB expression correlates with immune infiltration, particularly with CD8+ T cells and M1 macrophages. LDHB is also part of an immunometabolism-related signature for ccRCC diagnosis and therapeutic targeting. In hypoxic ccRCC, NDUFA4L2 acts as a mitochondrial checkpoint against ferroptosis, and LDHB is among the genes co-regulated with NDUFA4L2. ### 4.6 LDHB in Sepsis and Acute Kidney Injury LDHB is one of four diagnostic genes (APRT, ARG1, UMPS, LDHB) for sepsis prognosis. LDHB expression is reduced in sepsis patients, and this reduction correlates with disease severity and mortality. In acute kidney injury (AKI), lactate metabolism dysregulation, including altered LDHB expression, drives pathogenesis. LDHB may serve as a biomarker for early AKI diagnosis and a therapeutic target. ### 4.7 LDHB in Liver Disease In alcoholic liver disease (ALD), LDHB is identified as a hypoxia- and lactylation-related biomarker. LDHB expression is reduced in ALD, and this reduction is associated with increased histone lactylation and inflammation. In liver fibrosis, LDHB is among the amino acid metabolism-related biomarkers. In cows transitioning from pregnancy to lactation, LDHB expression in the liver is dynamically regulated, suggesting a role in metabolic adaptation. ### 4.8 LDHB in Skeletal Muscle and Metabolic Disorders LDHB expression in skeletal muscle is regulated by exercise and is altered in metabolic disorders. In type 2 diabetes, myoblast differentiation is impaired, and LDHB expression is reduced. SLC2A6 regulates myoblast differentiation by targeting LDHB, and restoring LDHB expression may improve muscle function in diabetic patients. In chickens selected for feed efficiency, LDHB expression is associated with glycolysis and oxidative stress pathways. In pigs, LDHB is a candidate gene for coarse feeding tolerance. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Epstein-Barr Virus (EBV) EBV encodes viral miRNAs that modulate host metabolism. **EBV-miR-BART1** is involved in regulating metabolism-associated genes in nasopharyngeal carcinoma (NPC), including LDHB. EBV-miR-BART1 downregulates LDHB expression, promoting the Warburg effect and enhancing NPC cell proliferation. This viral miRNA-mediated suppression of LDHB represents a mechanism by which EBV rewires host metabolism to support viral replication and tumorigenesis. ### 5.2 Human Adenovirus Manipulating lactate dehydrogenase genes, including LDHB, affects the metabolism of HEK-293 cells and the production of human adenovirus. Knockdown of LDHB alters the metabolic flux, reducing lactate consumption and increasing glucose uptake, which impacts viral replication efficiency. This suggests that LDHB is a host factor that can be targeted to modulate viral production in biopharmaceutical manufacturing. ### 5.3 African Swine Fever Virus (ASFV) In pigs, ASFV infection is associated with altered expression of immune and metabolic genes. Comparative analysis of ASFV-infected and surviving indigenous Doom pigs revealed differential expression of genes involved in glycolysis, including LDHB. The Doom pig breed, which is tolerant to ASFV, shows distinct LDHB expression patterns, suggesting a role for LDHB in antiviral immunity. ### 5.4 Lactococcus lactis and Bacterial LDHB In the bacterium Lactococcus lactis, the ldhB gene encodes a lactate dehydrogenase with distinct regulation and catalytic properties compared to the primary ldh gene. IS981-mediated adaptive evolution can recover lactate production by activating ldhB transcription in an ldh-deficient strain. This bacterial LDHB is important for industrial lactic acid production and serves as a model for understanding LDHB regulation. ### 5.5 Pichia pastoris and Fungal LDHB In the yeast Pichia pastoris (Komagataella phaffii), a novel homologous lactate transporter and LDHB are used to produce L-lactic acid from glycerol. Pyruvate decarboxylase knockout affects product distribution in strains engineered for lactic acid production, with LDHB playing a central role. These biotechnological applications highlight the versatility of LDHB across species. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 LDHB as a Therapeutic Target in Cancer Given its role in cancer metabolism, LDHB is an attractive therapeutic target. However, the context-dependent role of LDHB (tumor-suppressive in some cancers, oncogenic in others) complicates therapeutic strategies. **Cancers where LDHB inhibition is beneficial:** - **Triple-negative breast cancer (TNBC)**: LDHB is an essential gene in TNBC, and its silencing impairs tumor growth. Small-molecule inhibitors of LDHB could be effective in TNBC. - **Testicular germ cell tumors (TGCT)**: High LDHB expression is required for TGCT growth. LDHB inhibitors could be used to treat TGCT, particularly in patients with high serum LDH. - **Ovarian cancer**: LDHB promotes immune escape via PD-L1 activation. LDHB inhibition could enhance the efficacy of immune checkpoint inhibitors. - **Prostate cancer**: FGF signaling suppresses LDHB, and restoring LDHB expression (or inhibiting LDHA) could reverse the glycolytic phenotype. **Cancers where LDHB activation is beneficial:** - **Hepatocellular carcinoma (HCC)**: LDHB is epigenetically silenced, and low expression is associated with poor prognosis. Reactivating LDHB expression (e.g., via demethylating agents) could suppress tumor progression. - **Breast cancer (ER+)**: LDHB silencing is associated with tamoxifen resistance. Restoring LDHB expression could resensitize tumors to endocrine therapy. - **Colon adenocarcinoma (COAD)**: Low LDHB expression correlates with poor survival. LDHB activation could improve outcomes. ### 6.2 Small-Molecule Inhibitors of LDHB Several small-molecule inhibitors of LDH have been developed, though most target LDHA preferentially. Selective LDHB inhibitors are less common but are being explored: - **GNE-140**: A potent LDHA inhibitor with moderate LDHB activity. It inhibits lactate production and impairs tumor growth in xenograft models. - **FX11**: A competitive inhibitor of LDH with selectivity for LDHA over LDHB. It induces oxidative stress and inhibits tumor growth. - **GSK2837808A**: A selective LDHA inhibitor that also inhibits LDHB at higher concentrations. - **N-Hydroxyindole-based inhibitors**: These compounds target the NADH-binding site and show activity against both LDHA and LDHB. ### 6.3 LDHB in Radiotherapy and Chemotherapy Sensitization LDHB silencing enhances the effects of radiotherapy by impairing nucleotide metabolism and promoting persistent DNA damage. In lung cancer cells, LDHB knockdown reduces the expression of enzymes involved in de novo nucleotide synthesis (e.g., RRM2, TYMS), leading to decreased dNTP pools and increased sensitivity to ionizing radiation. This suggests that combining LDHB inhibition with radiotherapy could improve treatment outcomes in lung cancer. Similarly, LDHB silencing enhances the effects of chemotherapy. In breast cancer, miR-4677-3p-mediated LDHB downregulation contributes to paclitaxel resistance. Conversely, restoring LDHB expression could resensitize resistant cells to paclitaxel. In hepatocellular carcinoma, LDHB-mediated histone lactylation upregulates USP34, promoting cisplatin resistance. Targeting the LDHB-lactylation-USP34 axis could overcome chemoresistance. ### 6.4 LDHB in Metabolic Disorders LDHB is a potential target for metabolic disorders: - **Type 2 diabetes**: LDHB expression is reduced in diabetic muscle. Activating LDHB (e.g., via PPARβ/δ agonists) could improve muscle function and glucose homeostasis. - **Neurodegeneration**: LDHB deficiency causes mitochondrial dysfunction and neurodegeneration. LDHB activators could be neuroprotective. - **Alcoholic liver disease**: LDHB is reduced in ALD. Restoring LDHB expression could reduce inflammation and liver injury. - **Acute kidney injury**: LDHB is dysregulated in AKI. LDHB modulation could protect against renal injury. ### 6.5 Gene Therapy and CRISPR-Based Approaches - **AAV-mediated gene delivery**: AAV vectors expressing LDHB could be used to restore LDHB expression in tissues where it is deficient. This approach has been explored for TXNIP, a regulator of LDHB, in retinitis pigmentosa. - **CRISPR activation (CRISPRa)**: dCas9-VP64 targeting the LDHB promoter could react ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)